GRASPA Treatment for Patients With Acute Myeloblastic Leukemia

Acute Myeloid Leukemia Clinical Trial

— ENFORCE  

Official title:

A Multicenter, Open, Randomized, Controlled Phase IIb Trial Evaluating Efficacy and Tolerability of GRASPA (L-asparaginase Encapsulated in Red Blood Cells, Eryaspase) Plus Low-dose Cytarabine vs Low-dose Cytarabine Alone, in Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Elderly Patients, Unfit for Intensive Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01810705
• Other study ID #: GRASPA-AML2012-01
• Status: Completed
• Phase: Phase 2
• Start date: February 2013
• Est. completion date: November 10, 2017

Study information

• Verified date: February 2022
• Source: ERYtech Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The protocol aims at adding GRASPA (L-asparaginase encapsulated in red blood cells, eryaspase) to standard chemotherapy (low-dose cytarabine) to treat patients older than 65 years diagnosed with AML and unfit for intensive chemotherapy.

Description:

L-asparaginase (ASNase) holds a key role in chemotherapy for Acute Lymphoblastic Leukemia (ALL) in children and young adults. In elderly patients, its efficacy is counterbalanced by its toxicity, which impairs its use. However, a study conducted with GRASPA (L-asparaginase encapsulated in red blood cells, eryaspase) in elderly ALL (study reference "GRASPALL-GRAAL SA2 2008") showed that efficacy/safety profile was positive, paving the way for introducing ASNase benefit into chemotherapy for elderly patients. In adults, Capizzi (1988) reported a significant benefit of ASNase associated with high-dose cytarabine treatment (HiDAC) in Acute Myeloid Leukemia (AML). Indeed, there was an overall statistically superior complete remission rate for HiDAC/ASNase (40%) vs HiDAC (24%) and an overall survival benefit for patients treated with HiDAC/ASNase (19.6 weeks vs 15.9 weeks). Another study in elderly patients also displayed positive results for ASNase treatment (Petti, 1989), as well as recent single case reports that point out the potential benefit of ASNase in different AML or mixed lineage leukemia (Horikoshi, 2009; Rubnitz, 2009). Our preclinical results also showed that an AML cell line and blast cells from the bone marrow of AML patients were sensitive to ASNase in vitro. However, up to now, the toxicity of ASNase for elderly had prevented its use in this population that represents the majority of AML patients. Considering the promising results of ASNase for AML treatment and the better safety profile offered by GRASPA (L-aspariginase encapsulated in red blood cells, erysapase), a multicenter, randomized, controlled IIb trial is open for recruitment. Efficacy and tolerability of GRASPA plus low-dose cytarabine will be evaluated versus low-dose cytarabine alone in treatment of AML patients over 65 year-old, unfit for intensive chemotherapy. One hundred and twenty-three patients (65-85 year-old) newly diagnosed for AML are planned for inclusion in the study. A 2:1 randomization will be respected (82 patients treated with GRASPA® plus low-dose cytarabine and 41 patients treated with low-dose cytarabine alone). Each patient will be followed for 24 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 123
• Est. completion date: November 10, 2017
• Est. primary completion date: November 10, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years to 85 Years

Eligibility

Inclusion criteria:

• Patient > 65 years old and < 85 years old
• Newly diagnosed Acute Myeloid Leukemia (AML) or post myelodysplastic syndrome diagnosed within 6 months prior to study enrollment
• Unfit for intensive chemotherapy (at risk to suffer treatment related pejorative toxicities /early death) due to the presence of one or more of the following criteria: Dependence in activities of daily living owing to the presence of comorbidities other than those resulting from the deterioration caused by the neoplastic disease. Presence in the patient's medical history of three or more of the following comorbidities, even if they are under control with proper treatment: Congestive heart failure, other chronic cardiovascular diseases, chronic obstructive pulmonary disease, cerebrovascular disease, peripheral neuropathy, chronic kidney failure, hypertension, diabetes mellitus, systemic vasculitis, severe arthritis
• Presence of geriatric syndromes such as fecal or urinary incontinence, spontaneous bone fractures, mild and moderate dementia, or patients who fall repeatedly, or, patient unwilling to receive intensive chemotherapy
• Eligible to receive low-dose cytarabine treatment
• ECOG performance status = 2
• Female patients of childbearing potential and males must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment and for 6 months after the last dose of Cytarabine or 3 months after last dose of GRASPA (whichever is the longest).
• Negative serum pregnancy test at study entry for female subjects of childbearing potential
• Subscription to social security insurance (if applicable, in accordance with local regulations)
• Ability to understand, and willingness to sign, a written informed consent document and to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

Exclusion criteria:

• Patients with M3 AML of FAB classification (APL, acute promyelocytic leukemia)
• Patients with AML involving chromosome 16 abnormalities or translocation (8:21) (CBF-AML)
• Patient with secondary AML subsequent to prior malignant blood disorder such as:

Myelodysplastic syndrome diagnosed more than 6 months before study entry or Myeloproliferative syndrome

• Prior therapy to AML (standard therapy or investigational agents)
• Inadequate organ function : Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis, Serum creatinine concentration > 2 x ULN (Upper Limit of Normal), AST or ALT levels > 3.5xULN or 5xULN if related to AML, Total bilirubin > 2 x ULN, INR > 1.5, unless patient under chronic treatment with anticoagulants (in this case, INR should be within expected ranges for the specific condition), Insulin-dependent or uncontrolled diabetes mellitus
• Concurrent malignancies other than AML requiring chemotherapy
• Severe active infection, HIV seropositivity, or known active type B or C viral hepatitis
• Known or suspected hypersensitivity or intolerance to mannitol
• Breastfeeding or lactating women

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• GRASPA
Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum

Locations

Country	Name	City	State
France	Groupe Hospitalier Sud	Amiens	Somme
France	Chu D'Angers	Angers	Maine Et Loire
France	Hôpital JEAN MINJOZ	Besancon	Doubs
France	Hopital Morvan	Brest	Finistere
France	CHU Estaing	Clermont-ferrand	Puy De Dome
France	Hôpital Claude-Huriez	Lille	Nord
France	Centre Léon Bérard	Lyon	Rhone Alpes
France	Institut Paoli Calmettes	Marseille	Bouche Du Rhone
France	Hôpital Saint Eloi	Montpellier	Hérault
France	Hôtel Dieu - CHU de NANTES	Nantes	Loire Atlantique
France	Hôpital l'Archet 1	Nice	Alpes Maritimes
France	CHRU de Nîmes	Nimes	Guard
France	hopital de Perpignan	Perpignan	Pyrénées Orientales
France	Hôpital Haut-Lévèque	Pessac	Gironde
France	Centre hospitalier Lyon Sud	Pierre Benite	Rhone Alpes
France	Hopital Région d'Annecy	Pringy	Haute Savoie
France	Centre Henri Becquerel	Rouen	Seine Maritime
France	Institut de Cancérologie de la Loire	Saint-priest-en-jarez	Loire
France	Hopital de Hautepierre	Strasbourg	Haut Rhin
France	Hopital De Purpan CHU Toulouse	Toulouse	Haute Garonne
France	Hopital de Brabois	Vandoeuvre Les Nancy	Meurthe Et Moselle

Sponsors (1)

Lead Sponsor	Collaborator
ERYtech Pharma

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival	OS is defined as the time elapsed between randomization and death from any cause.	Each patient will be followed for a duration of 24 months.
Secondary	Response to Treatment	Percentage of patients with Complete remission (CR), Complete remission with incomplete recovery (neutrophil or platelet regeneration, CRi), Partial remission (PR)	Each patient will be followed for a duration of 24 months.
Secondary	Progression Free Survival (PFS)	Defined as the time elapsed between randomization and resistant disease or relapse or death from any cause	Each patient will be followed for a duration of 24 months.
Secondary	Patient Quality of Life	Collecting survey about patients quality of life	Each patient will be followed for a duration of 24 months.
Secondary	Safety of GRASPA Adverse Events and Serious Adverse Events	Number of incidences, type, severity and causality of adverse events / serious adverse events	Each patient will be followed for a duration of 24 months.
Secondary	Relapse Free Survival	Defined only for patients who achieve CR or CRi as the time elapsed between date of CR/CRi and date of disease relapse or death from any cause	Each patient will be followed for a duration of 24 months.
Secondary	Number of Hospitalizations	Hospitalizations (except schedule protocol visit during the study)	Each patient will be followed for a duration of 24 months.
Secondary	Percentage of Patients Who Need Transfusions	Number of transfusions per patient (red blood cells and or platelets)	Until patient stops treatment (expected average of 8 months)
Secondary	Pharmacodynamic and Pharmacokinetic Parameters of GRASPA	Plasma concentrations of asparagine, aspartate, glutamine, glutamate, whole blood L- asparaginase activity	Until patient stops treatment (expected average of 8 months)
Secondary	Immunogenicity	Titer of anti L-asparaginase antibodies	Until patient stops treatment (expected average of 8 months)
Secondary	Asparagine Synthetase (Optional)	Asparagine synthetase and in vitro sensitivity to aspariginase on the harvested bone marrow cells	Until patient stops treatment (expected average of 8 months)
Secondary	Biomarker Cytogenetic Testing (Optional)	Defined as cytogenetic biomarker testing	Until patient stops treatment (expected average of 8 months)